JAMA: Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension – The Target-HTN Randomized Clinical Trial September 11, 2023 2:04 PM
JAMA Editorial: A New Dawn for Aldosterone as a Therapeutic Target in Hypertension September 10, 2023 9:07 AM
AHA Hypertension 2023 Presentation: Target-HTN Trial on the Safety and Efficacy of Lorundrostat (MLS-101) in Patients With Uncontrolled Hypertension September 10, 2023 8:00 AM
ACC 2023 Poster: First-In-Human Study of lorundrostat, a Potent and Highly Selective Aldosterone Synthase Inhibitor March 5, 2023 2:30 PM
ACC 2023 Poster: Highly Effective Blood Pressure Lowering with lorundrostat, a New Aldosterone Synthase Inhibitor, in Individuals with Obesity and RAAS Dysregulation March 4, 2023 4:30 PM
